Neurodegenerative Diseases Therapeutics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The Neurodegenerative Diseases Therapeutics Market size is set to grow by USD 19.74 billion from 2022 to 2028, progressing at a CAGR of 7%.

Neurodegenerative diseases involve the gradual loss of function and structure of neurons, sometimes including the death of neurons. A major cause of neurodegeneration is the build-up of toxic protein substances in the brain, which interferes with the functioning of mitochondria in the brain. Some neurodegenerative diseases, such as Huntington’s disease and spinal cerebellar ataxia, are caused by genetic mutations resulting from the dilation of CAG trinucleotides and poly Q ducts. Some neurodegenerative diseases result from the aggregation of misfolded proteins (such as Alzheimer’s, Huntington’s, and Parkinson’s). One of the common factors of apoptosis in neurodegeneration is the endogenous mitochondrial apoptosis pathway, for example, amyotrophic lateral sclerosis. Alzheimer’s disease is caused by the aggregation of misfolded proteins. Parkinson’s disease affects the central nervous system due to the abnormal accumulation of the protein alpha-synuclein bound to ubiquitin in damaged cells. Huntington’s disease is a genetic disorder in which nerve cells in the brain are destroyed.

Market Segments

By Indication

• Multiple sclerosis
• Alzheimers disease
• Parkinsons disease
• Huntingtons disease

Key Players

• AB Science SA
• AbbVie Inc.
• Acadia Pharmaceuticals Inc.
• Biogen Inc.
• F. Hoffmann La Roche Ltd.
• H Lundbeck AS
• Mitsubishi Chemical Holdings Corp.
• Novartis AG
• Sanofi
• Teva Pharmaceutical Industries Ltd.

Scope of the Report

The research study analyzes the global Neurodegenerative Diseases Therapeutics industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment

Geographic Coverage

o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume

Key Questions Answered by Neurodegenerative Diseases Therapeutics Market Report

1. What was the Neurodegenerative Diseases Therapeutics Market size in 2020 and 2021; what are the estimated growth trends and market forecast (2022-2028).

2. What will be the CAGR of Neurodegenerative Diseases Therapeutics Market during the forecast period (2022-2028)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
4. Which manufacturer/vendor/players in the Neurodegenerative Diseases Therapeutics Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.